“Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s664. doi:10.25251/h3w8px06.